Protocole d`essai clinique de phase 3 pour Texopi ® accepté par la

!
"#!!$%&!#'()*(!+!$%&,-./.!#)0102034!56477(8!23898:;4!54!<'(74!===!(224<1>!<()!3(!?@A!41!36&BA!!
!
OSE$Pharma$:$$
Protocole$d’essai$clinique$de$phase$3$pour$OSE92101$accepté$par$la$FDA$et$l’EMA$
!
OSE$ Pharma$ reçoit$ les$ avis$ positifs$ pour$ préparer$ l’essai$ clinique$ de$ phase$ 3$ d’enregistrement$ pour$
OSE92101,$son$vaccin$thérapeutique$contre$le$cancer$du$poumon$«$non$à$petites$cellules$»$(NSCLC)!
!
Paris,$ 23$juin$ 2014! C! $%&! #'()*(! %AD! 7028>1>! E80<'()*(24;18:;4! :;8! 209F081! 41! 5>G430<<4! 547! <)05;817!
568**;901'>)(<84!2091)4!34!2(924)!H)I24!J!;94!142'9030H84!*;318,><810<47!58)8H>4!2091)4!K!(918HL947!1;*0)(;MD!
(990924!(G08)!0E149;!;9!(G87!N(G0)(E34!<0;)!709!<)0102034!54!<'(74!O!30)7!54!3(!)>;9809!54!N89!54!#'(74!-!41!!54!
<)>,#'(74!O!(G42! 36(H4924! (*>)82(894! 5;! *>582(*491! P?@AQR! S(!7028>1>! (! >H(34*491! )4F;! ;9! (G87! 7284918N8:;4!
<07818N!20920)5(91!54!36(H4924!4;)0<>4994!547!*>582(*4917!P&BAQ!7;)!34!*T*4!<)0102034R!!
$%&,-./.!471! ;9!G(2289! 1'>)(<4;18:;4! *;318,><810<47! <)05;87(91! ;94! )><0974! 7<>28N8:;4! U! 2V1010M8:;4!<0;)! 34!
1)(814*491! 5;!2(924)! 5;! <0;*09! W!909!J! <418147!2433;347!X!J!;9!71(54!(G(92>!PY%"S"Q! 2'4Z! 347! <(184917![SA,A-!
<07818N7R!"4!1)(814*491!74)(!>G(3;>!49!54;M8L*4!38H94D!<0;)!547!<(184917!<0;)!347:;437!;9!1)(814*491!54!<)4*8L)4!
38H94!96(!<(7!>1>!4NN82(24R!@4<;87!N>G)84)!-/.OD!$%&,-./.!(!0E149;!54!3(!?@A!34!71(1;1!0)<'4389!(;M!&1(17,\987!5(97!
34!2(924)!5;!<0;*09!W!909!J!<41814!2433;347!X![SA,A-!<07818NR!
$
OSE$Pharma$prévoit$de$démarrer$son$étude$pivot$de$Phase$3$sur$le$1er$semestre$2015!
!
S6477(8!<8G01!54!#'(74!O!<0)14)(!7;)!547!<(184917!(1148917!56;9!2(924)!89G(78N!54!71(54!===E!0;!547!<(184917!(1148917!
56;9!2(924)!Y%"S"!*>1(71(18:;4!54!71(54!=]D!:;8!4M<)8*491!34!)>24<14;)![SA,A-!P^K_!54!3(!<0<;3(1809!(1148914!54!
Y%"S"QD!)>24<14;)!23>! 54!3(!)><0974! 2V1010M8:;4R! S6>1;54!<)>G081!K//!<(184917!(;M!&1(17,\987!41! 49! &;)0<4!`!4334!
20*<()4)(! $%&,-./.! (;M! 71(95()57! 1'>)(<4;18:;47!(21;437! P50241(M43! 0;! <4*41)4M45QR! "47! 54;M! (H4917!
2'8*801'>)(<8:;47!7091!347!1)(814*4917!54!)>N>)4924!49!7420954!38H94!<0;)!24114!<0<;3(1809!54!<(184917R!S4!2)81L)4!
56>G(3;(1809! <)8928<(3! 54! 36477(8! 74)(! 3(!7;)G84! H30E(34R! S47! 2)81L)47! 56>G(3;(1809!742095(8)47! 54! 36>1;54!
20*<)499491!3(!7;)G84!7(97!<)0H)477809!54!3(!*(3(584!P#?%QD!3(!:;(381>!54!G84D!34!1(;M!54!)><0974!H30E(3!P$aaQ!41!3(!
7>2;)81>R!U0;7!347!<()(*L1)47!23>7!54!36477(8!<8G01!54!#'(74!O!091!>1>!)4G;7!(G42!3(!?@A!41!36&BAR!!
$%&,-./.!471!;94!20*E89(8709!E)4G41>4!54!58M!><810<47!P<4<18547!7V91'>18:;47Q!7>34218099>7!41!0<18*87>7!!J!<()18)!!
54!289:!(918HL947!1;*0)(;MR!"47!58M!><810<47!H>9L)491!;94!)><0974!7<>28N8:;4!547!2433;347!U!2V1010M8:;47!58)8H>47!
2091)4!347!2433;347!2(92>)4;747!:;8!4M<)8*491!36;9!54!247!(918HL947!1;*0)(;MR!S(!<)>74924!54!247!289:!(918HL947!
1;*0)(;M!P[&a,-b94;D!<KOD!"&AD!BAc&,-!41!BAc&,OQ!41!364M<)477809!547!)>24<14;)7![SA,A-!7091!547!N(214;)7!54!
*(;G(87!<)0907182!54!<3;784;)7!1V<47!54!2(924)R!@(97!!34!2(924)!5;!<0;*09D!83!4M8714!;9!8*<0)1(91!E47089!*>582(3!
<0;)!;9!1)(814*491!E849!103>)>D!<)0309H4(91!3(!7;)G84!H30E(34!547!<(184917!41!(*>380)(91!3(!7;)G84!7(97!<)0H)477809!
54!3(!*(3(584R!!
W!Je#me#réjouis#de#cette#réponse#positive#simultanée#de#la#part#des#deux#agences,##la#FDA#et#l’EMA,#pour#l’essai#pivot#
de#Phase#3#d’OSEB2101#chez#des#patients#atteints#de#cancers#à#un#stade#avancé.#Nous#disposons#maintenant#d’un##
plan#de#marche#précis#pour#ce#que#nous#croyons#être#une#nouvelle#forme#prometteuse#d’immunothérapie#du#cancer.#
Compte# tenu# de# ma# forte# implication#dans# le# développement# d’OSEB2101,# je# suis# convaincu# que# ce# vaccin#
thérapeutique# multiBépitopes# apportera# de# nombreux# avantages#cliniques# aux# patients# atteints# d’un# cancerXD!
5>23()4!&*834!S0)8(D!#)>785491!56$%&!#'()*(R!
!

!
"#!!$%&!#'()*(!+!$%&,-./.!#)0102034!56477(8!23898:;4!54!<'(74!===!(224<1>!<()!3(!?@A!41!36&BA!!
!
!
!
W!Nous#préparons##activement##le#lancement#de#l’étude#de#Phase#3#pour#OSEB2101,#à#la#fois#en#termes#de#logistique#
d’essai# clinique# et# de# fabrication# des# lots# industriels# nécessaires# à# cet# essai,# prévu# pour# démarrer# au# premier#
semestre#2015#X!(d0;14!@0*898:;4!"0971(91898D!@8)421)824!c>9>)(34!56$%&!#'()*(R$
$
$
Des$résultats$positifs$pour$l’étude$clinique$de$phase$II$d’OSE92101$
!
$%&,-./.!(!N(81!360Ed41D!(;M!&1(17,\987D!56;94!>1;54!*;3182491)8:;4!54!#'(74!-!:;8!(!*87!49!>G854924!364NN82(281>!54!
709!G(2289!1'>)(<4;18:;4!:;8!(;H*4914!3(!)><0974!7<>28N8:;4!U!2V1010M8:;4!41!:;8!(*L94!;94!(;H*491(1809!54!3(!
7;)G84!(77028>4!J!;94!E0994!103>)(924R!$
S(!7;)G84!*>58(94!547!<(184917!1)(81>7!(G42!$%&,-./.!30)7!54!24114!>1;54!54!#'(74!-!>1(81!54!.eDO!*087D!2091)4!.-!
*087!<0;)!34!H)0;<4!54!2091)f34!20*<07>!54!<(184917![SA,A-!9>H(18N7R! \94!)><0974!U! 2V1010M8:;4!547!<(184917!
1)(81>7!(G42!$%&,-./.!(!>1>!20971(1>4!5(97!g._!547!2(7D!(G42!;94!)><0974!8**;94!J!(;!*0897!;9!><810<4!877;!!5;!
G(2289R! \94! 20))>3(1809! 78H98N82(18G4!P<h/D//.Q! (! >1>! 0E74)G>4! 491)4! 3(!5;)>4! 54! 7;)G84! 547! <(184917! 1)(81>7! (G42!
$%&,-./.!41!36(*<34;)!547!)><09747!8**;947!(;M!><810<47!0E74)G>47!<0;)!247!<(184917R!"4114!>1;54!<0)1(81!7;)!
.OK! <(184917! (1148917! 54! Y%"S"R! #()*8! 4;MD! i^! <(184917! [SA,A-! <07818N7! 091! )4F;! 34! 1)(814*491! $%&,-./.!41!e.!
<(184917![SA,A-!9>H(18N7!091!20*<07>!34!H)0;<4!2091)f34!P89N0)*(18097!N0;)9847!7;)! 3(!7;)G84!J!;9! (9QR!U0;7!347!
<(184917!>1(8491!(1148917!54!3(!*(3(584!J!;9!71(54!(G(92>!P2(924)!89G(78N!54!71(54!===E!0;!2(924)!*>1(71(18:;4!54!
71(54! =]Q!`! ie_! 56491)4! 4;M! !>1(8491! J! ;9! 71(54! *>1(71(18:;4R! S47! <(184917! :;8! 091! <()1828<>! J! 36>1;54! (G(8491!
(;<()(G(91!>1>!30;)54*491!1)(81>7D!iKDK_!56491)4!4;M!(G(8491!)4F;!<3;7!54!54;M!38H947!54!1)(814*491R!!
$
A$propos$d’OSE$Pharma$
$%&! #'()*(! 471! ;94! 7028>1>! E80<'()*(24;18:;4! :;8! 209F081! 41! 5>G430<<4! 547! <)05;817! 568**;901'>)(<84! PG(22897!
1'>)(<4;18:;47!*;318,><810<47Q!2091)4!34!2(924)!H)I24!J!;94!142'9030H84!:;8!(;H*4914!3(!)><0974!7<>28N8:;4!U!2V1010M8:;4!R!
! !
S4!<)05;81!34!<3;7!(G(92>!56$%&!#'()*(D!$%&,-./.D!N4)(!360Ed41!56;94!>1;54!<8G01!54!#'(74!O!(;M!&1(17,\987!41!49!&;)0<4D!5(97!
34!!2(924)!5;!<0;*09!W!909!J!<418147!2433;347!X!PY%"S"QR!#()!(8334;)7D!$%&,-./.!<4;1!>H(34*491!T1)4!5>G430<<>!49!#'(74!-!5(97!
56(;1)47! 89582(18097! 49! 092030H84! P0G(8)47D! 20309D! 74897D! <)071(14Q!`! 83! 471! 49G87(H>! 49!20*E89(8709! (G42! 56(;1)47! <)05;817!
568**;901'>)(<84R!!
$%&,-./.!G874!289:!(918HL947!1;*0)(;M!PUAAQR!=37!091!>1>!7>34218099>7!2()!34;)!<)>74924!471!38>4!J!;9!*(;G(87!<)0907182!41!J!3(!
H)(G81>!54!<3;784;)7!2(924)7R!$%&,-./.!20918491!58M!><810<47!0<18*87>7D!5>)8G>7!54!247!289:!(918HL947!1;*0)(;MD!!:;8!H>9L)491!
54!N0)147!)><09747!7<>28N8:;47!54!2433;347!U!2V1010M8:;47D!2095;87(91!34!7V71L*4!8**;981(8)4!J!>38*894)!347!2433;347!1;*0)(347!
:;8!4M<)8*491!247!(918HL947!1;*0)(;MR!!
!
@4<;87! -/.-! $%&! #'()*(! 471! H>)>4! <()! &*834! S0)8(! 41! @0*898:;4! "071(91898D! 54;M! 491)4<)494;)7! 4M<>)8*491>7! 54! 3(!
E80142'9030H84R! S(! 7028>1>! 471! E(7>4! J! #()87D! J! 36'f<81(3! "02'89R! &9! -/.^D! 3(! 7028>1>! (! N89(387>! 36(2:;8781809! 547! (218N7! 54! 3(!
142'9030H84! $%&,-./.D! 547! 5)0817! *0958(;M! 41! 5;! 7(G08),N(8)4! 20994M4R! S6(2:;8781809! 56$%&,-./.! 74! N0954! 7;)! 364M<>)84924!
56&*834!S0)8(!:;8!(!>1>D!49!1(91!:;6(92849!"&$!56&<8**;94D!J!3689818(18G4!5;!<(77(H4!49!5>G430<<4*491!23898:;4!54!24!<)05;81!
90G(14;)!54!368**;901'>)(<84!5;!2(924)R!
!
!
!
$
$

!
"#!!$%&!#'()*(!+!$%&,-./.!#)0102034!56477(8!23898:;4!54!<'(74!===!(224<1>!<()!3(!?@A!41!36&BA!!
$
$
$
Cancer$du$poumon$
S4!2(924)!5;!<0;*09!471!3(!2(;74!<)8928<(34!54!5>2L7!(77028>4!(;!!2(924)!5(97!34!*0954R!"'(:;4!(99>4D!34!90*E)4!54!5>2L7!
38>7!(;!2(924)!5;!<0;*09!471!7;<>)84;)! J!24;M!)>7;31(91!547!2(924)7!5;!2f309D!5;!7489! 41!54! 3(!<)071(14!)>;987R!%4309!34!7814!
56><85>*8030H84! 54! c30E02(9! P=Aa"! -/.-QD! 34! 2(924)! 5;! <0;*09! P54! 1V<4! W!909! J! <418147! 2433;347!XD! Y%"S"! 41! W!J! <418147!
2433;347!XQ!10;2'4!<3;7!54!.DKj!*8338097!54!<(184917!<()!(9!41!2(;74!<)L7!54!.DOg!*8338097!54!5>2L7!<()!(9!P<)L7!54!i//!///!49!
&;)0<4D!-jj!///!5(97!36&;)0<4!547!-eD!-.^!///!(;M!&1(17,\987!41!.^.!///!(;!k(<09QR!&9G8)09!jK!J!jj_!547!2(924)7!5;!<0;*09!
7091! 54! 1V<4! W!909! J! <418147! 2433;347!XR! S(! *(d0)81>! 547! <(184917! 7091! J! ;9! 71(54! (G(92>! 54! 34;)! *(3(584! (;!*0*491! 5;!
58(H907182!+!2(924)!89G(78N!54!71(54!===!0;!2(924)!*>1(71(18:;4!54!71(54!=]R!&9!5><81!54!1)(814*4917!(H)4778N7D!347!1(;M!)43(18N7!54!
7;)G84!J!289:!(97!7091!5649G8)09!._!!<0;)!347!<(184917!(1148917!56;94!*(3(584!*>1(71(18:;4!P71(54!=]QR!
$
$
$
Contacts$presse$
!
$
OSE$Pharma$sa!
@0*898:;4!"071(91898D!@8)4214;)!c>9>)(3!
50*898:;4R2071(91898l074<'()*(R20*!!
B0E!mOO!i!.O!-/!ee!^g!!
!
A34M87!#4V)0347D!@A?!
A34M87R<4V)0347l074<'()*(R20*!
B0E!+!mOO!i!..!K.!.g!ee!
!
!
HB$ComCorp$$
?30)4924!#0)14d084!!
mOO!.!Kj!.j!O-!Kj!b!mOO!i!jj!j^!j.!e^!!
N<0)14d084l20*20)<RN)!
!
A994![()5V!
mOO!.!Kj!.j!O-!K.!b!mOO!i!.O!Ki!-O!gi!
('()5Vl20*20)<RN)!
!
$
Citigate$Dewe$Rogerson$
S(;)4924!n(;31!!
mOO!.!KO!O-!j^!ej!!
3(;)4924RE(;31l2818H(14RN)!!!
!
S;284!S()H;84)$
mOO!.!KO!O-!j^!eK!
3;284R3()H;84)l2818H(14RN)!
!
!
!
!